On June 5, 2019 EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, reported the closing of a $74 million USD Series B financing round (Press release, EpimAb Biotherapeutics, JUN 5, 2019, View Source [SID1234536901]). The financing was co-led by SDIC Fund and Sherpa Healthcare Partners, and also included investments from SCVC, further private investment entities, and the A round investors, bringing the total funding so far to over $100M USD. With the funding, EpimAb will continue to advance its clinical PhI/II program EMB01 and expand its clinical pipeline of multiple therapeutic candidates into immuno-oncology and other areas with highly unmet medical needs. In addition, EpimAb is expanding its current capacities with the addition of a new CMC site in Suzhou for process development and pilot manufacturing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The completion of our Series B financing will allow the Company to accelerate transforming into a mid-size company, rapidly growing and advancing a pipeline based on our own discovery efforts," said Chengbin Wu, PhD, founder and CEO of EpimAb Biotherapeutics. "We are very proud to have grown from foundation on internal innovation to where we are today within less than 4 years and we greatly appreciate the support we’ve received from our existing and new investors, as well as their beliefs in our technologies that have demonstrated advantages in developing breakthrough biologics therapies."

EpimAb is creating a pipeline of novel proprietary bispecific antibody therapeutics with a strong focus on oncology and other areas of high values to patients. With the successful close of the B round, both Dongfang Li from SDIC Fund and Cheng Xing from Sherpa will join the Board of EpimAb with immediate effect. Next to Dr. Wu, the management of EpimAb consists of Dr. Stephan Lensky, leading the financing and BD efforts as COO and CBO, and Dr. Bin Peng, CMO, heading the translational and clinical development programs at EpimAb.

"EpimAb has been emerging as one of the most innovative Shanghai-based biotech companies with a global vision," said Dongfang Li, Director at SDIC Fund. "With EpimAb’s proprietary platform, strong science portfolio and well-orchestrated management, we are confident of its development in the upcoming years and have determined to become part of this exciting and unique enterprise."

"We have followed and recognized EpimAb’s rapid growth and progress in the past few years," said Cheng Xing, Managing Partner at Sherpa. "We are optimistic about its ongoing research progress and reinforcement of its position as a global leading bispecific antibody company with potential treatments benefiting more patients worldwide."

On June 5, 2019 DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, reported the closing of its previously announced registered direct offering of 1,170,000 shares of common stock and, in a concurrent private placement, warrants to purchase 760,500 shares of common stock at a combined purchase price of $3.10 per share and related warrant (Press release, DelMar Pharmaceuticals, JUN 5, 2019, View Source [SID1234536900]). The warrants have an exercise price of $3.10 per share, are immediately exercisable and have a term of exercise of five years. The gross proceeds from the offering, prior to deducting offering expenses and placement agent fees and expenses payable by the Company, were $3.6 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Maxim Group LLC acted as the lead placement agent and Dawson James Securities, Inc. acted as co-placement agent in connection with the transaction.

The shares of common stock described above were offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-213601), that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective on September 27, 2016. A final prospectus supplement and accompanying prospectus relating to the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention: Syndicate Department, or via email at [email protected] or telephone at (212) 895-3745.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On June 5, 2019 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, reported that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the Goldman Sachs 40th Annual Global Healthcare Conference on June 11 in Rancho Palos Verdes, Calif (Press release, Turning Point Therapeutics, JUN 5, 2019, View Source [SID1234536899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Countouriotis’ session is scheduled to begin at 1:20 p.m. PT/4:20 p.m. ET and will be accessible via an audio webcast through the Investors page of www.tptherapeutics.com.

On June 5, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is reported that it was involved in two poster presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) Annual Meeting, in Chicago, Illinois taking place from May 31st – June 4, 2019 (Press release, Immutep, JUN 5, 2019, View Source [SID1234536898]). The two posters related to Immutep’s lead product candidate eftilagimod alpha ("efti" or "IMP321").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first poster (TPS2667 – #299b) provided an overview of the ongoing Phase II TACTI-002 (Two ACTive Immunotherapies) clinical trial. TACTI-002 is being conducted by Immutep in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as "MSD" outside the United States and Canada). This multicenter Phase II clinical trial is evaluating the combination of efti with MSD’s KEYTRUDA (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

This poster, presented by Dr. Julio Antonio Peguero, MD of Oncology Consultants PA, 2130 W. Holcombe Blvd. 10th Floor, Houston, TX 77030, outlined the ongoing TACTI-002 clinical trial, its design and primary end points.

The second poster related to efti (TPS2651 – #291b) provided an overview of the two additional INSIGHT clinical trial stratas of the prospective investigator-initiated phase I study. Stratum D of the clinical trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. This explorative, open-labeled Phase I study will evaluate the feasibility and safety of subcutaneous efti injections combined with either standard-of-care drug therapy or BAVENCIO (or avelumab, PD-L1 inhibitor) in patients with advanced-stage solid tumors. The Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany ("IKF") will be the sponsor of the clinical trial and it will be conducted under the existing protocol of the ongoing INSIGHT clinical study. Stratum D is open for recruitment.

This poster, presented by Dr. Daniel Wilhelm Mueller, PhD, of the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany, outlined the planned two new strata of the INSIGHT clinical trial, its design and primary end points.

The ASCO (Free ASCO Whitepaper) poster regarding the Company’s TACTI-002 trial can be found at View Source

Avelumab Approved Indications

Avelumab (BAVENCIO) in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

The US Food and Drug Administration (FDA) also granted accelerated approval for avelumab (BAVENCIO) for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Avelumab is currently approved for patients with MCC in more than 45 countries globally, with the majority of these approvals in a broad indication that is not limited to a specific line of treatment.

Avelumab Important Safety Information from the US FDA-Approved Label

The warnings and precautions for avelumab (BAVENCIO) include immune-mediated adverse reactions (such as pneumonitis and hepatitis [including fatal cases], colitis, endocrinopathies, nephritis and renal dysfunction and other adverse reactions [which can be severe and have included fatal cases]), infusion-related reactions, major adverse cardiovascular events (MACE), and embryo-fetal toxicity.

Common adverse reactions (reported in at least 20% of patients) in patients treated with BAVENCIO include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, peripheral edema, decreased appetite/hypophagia, urinary tract infection and rash. Additional common adverse reactions reported in patients receiving BAVENCIO in combination with axitinib include hypertension, mucositis, palmar-plantar erythrodysesthesia, dysphonia, hypothyroidism, hepatotoxicity, cough, dyspnea, abdominal pain, and headache. Clinical chemistry and hematology laboratory value abnormalities have been reported including but not limited to grade 3-4 lymphopenia, anemia, elevated cholesterol and liver enzymes.

For full Prescribing Information and Medication Guide for BAVENCIO, please see www.BAVENCIO.com.

About Immutep

On June 5, 2019 Ningbo NewBay Medical Technology Co., Ltd. (Headquarters in Ningbo, China, CEO: Zhenhai Shen; NewBay), reported that NewBay initiated a Phase I clinical study of the EP4 antagonist AAT-007 (generic name: grapiprant) in the People’s Republic of China (China) on June 4, 2019 (Press release, AskAt, JUN 5, 2019, View Source [SID1234536869]). NewBay is a subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. (Tai Kang) which licensed AT-007 from AskAt Inc. for cancer therapy in China. This is the first clinical trial of AAT-007 in China targeting cancer. AskAt will receive a milestone payment from Tai Kang in conjunction with the initiation of the study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!